Cargando…

New advances in amblyopia therapy II: refractive therapies

The treatment of anisometropic or ametropic amblyopia has traditionally enjoyed a high treatment success rate. Early initiation and consistent use of spectacle correction can completely resolve amblyopia in a majority of patients. For those with anisometropic amblyopia that fail to improve with glas...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraus, Courtney L, Culican, Susan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287570/
https://www.ncbi.nlm.nih.gov/pubmed/29871968
http://dx.doi.org/10.1136/bjophthalmol-2018-312173
_version_ 1783379665311760384
author Kraus, Courtney L
Culican, Susan M
author_facet Kraus, Courtney L
Culican, Susan M
author_sort Kraus, Courtney L
collection PubMed
description The treatment of anisometropic or ametropic amblyopia has traditionally enjoyed a high treatment success rate. Early initiation and consistent use of spectacle correction can completely resolve amblyopia in a majority of patients. For those with anisometropic amblyopia that fail to improve with glasses wear alone, patching or atropine penalisation can lead to equalisation of visual acuity. However, successful treatment requires full-time compliance with refractive correction and this can be a challenge for a patient population that often has one eye with good acuity without correction. Other barriers for a select population with high anisometropic  or ametropic amblyopia include rejection of glasses for various reasons including discomfort, behavioural or sensory problems, postural issues and visually significant aniseikonia. When consistent wear of optical correction proves difficult and patching/atropine remains a major obstacle, surgical correction of refractive error has proven success in achieving vision improvement. Acting as a means to achieve spectacle independence or reducing the overall needed refractive correction, refractive surgery can offer a unique treatment option for this patient population. Laser surgery, phakic intraocular lenses and clear lens exchange are three approaches to altering the refractive state of the eye. Each has documented success in improving vision, particularly in populations where glasses wear has not been possible. Surgical correction of refractive error has a risk profile greater than that of more traditional therapies. However, its use in a specific population offers the opportunity for improving visual acuity in children who otherwise have poor outcomes with glasses and patching/atropine alone.
format Online
Article
Text
id pubmed-6287570
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-62875702018-12-27 New advances in amblyopia therapy II: refractive therapies Kraus, Courtney L Culican, Susan M Br J Ophthalmol Review The treatment of anisometropic or ametropic amblyopia has traditionally enjoyed a high treatment success rate. Early initiation and consistent use of spectacle correction can completely resolve amblyopia in a majority of patients. For those with anisometropic amblyopia that fail to improve with glasses wear alone, patching or atropine penalisation can lead to equalisation of visual acuity. However, successful treatment requires full-time compliance with refractive correction and this can be a challenge for a patient population that often has one eye with good acuity without correction. Other barriers for a select population with high anisometropic  or ametropic amblyopia include rejection of glasses for various reasons including discomfort, behavioural or sensory problems, postural issues and visually significant aniseikonia. When consistent wear of optical correction proves difficult and patching/atropine remains a major obstacle, surgical correction of refractive error has proven success in achieving vision improvement. Acting as a means to achieve spectacle independence or reducing the overall needed refractive correction, refractive surgery can offer a unique treatment option for this patient population. Laser surgery, phakic intraocular lenses and clear lens exchange are three approaches to altering the refractive state of the eye. Each has documented success in improving vision, particularly in populations where glasses wear has not been possible. Surgical correction of refractive error has a risk profile greater than that of more traditional therapies. However, its use in a specific population offers the opportunity for improving visual acuity in children who otherwise have poor outcomes with glasses and patching/atropine alone. BMJ Publishing Group 2018-12 2018-06-05 /pmc/articles/PMC6287570/ /pubmed/29871968 http://dx.doi.org/10.1136/bjophthalmol-2018-312173 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
Kraus, Courtney L
Culican, Susan M
New advances in amblyopia therapy II: refractive therapies
title New advances in amblyopia therapy II: refractive therapies
title_full New advances in amblyopia therapy II: refractive therapies
title_fullStr New advances in amblyopia therapy II: refractive therapies
title_full_unstemmed New advances in amblyopia therapy II: refractive therapies
title_short New advances in amblyopia therapy II: refractive therapies
title_sort new advances in amblyopia therapy ii: refractive therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287570/
https://www.ncbi.nlm.nih.gov/pubmed/29871968
http://dx.doi.org/10.1136/bjophthalmol-2018-312173
work_keys_str_mv AT krauscourtneyl newadvancesinamblyopiatherapyiirefractivetherapies
AT culicansusanm newadvancesinamblyopiatherapyiirefractivetherapies